TG THERAPEUTICS, INC. 8-K

What Happened
TG Therapeutics, Inc. announced on March 20, 2026 (filing date) that it closed a First Amendment to its financing agreement on March 18, 2026, establishing a $750 million term loan (the "2026 Term Loan") that was borrowed in full at closing. A portion of the proceeds repaid the company’s prior initial term loans in full. The amendment also creates an uncommitted additional facility of up to $250 million.

Key Details

• Closing Date: March 18, 2026; Filing Date: March 20, 2026.
• Principal: $750 million term loan borrowed in full at closing; plus an uncommitted additional facility up to $250 million.
• Maturity: Term Loan Maturity Date is March 18, 2031.
• Interest: Borrowings accrue interest = applicable margin + borrower’s choice of (a) a base rate (highest of prime, fed funds +0.50%, Term SOFR +1.00%, or 2.00%) or (b) Term SOFR (floor 1.00%). Pricing grid margins start at 4.75% for SOFR borrowings and 3.75% for base rate borrowings, with a 25 bp step-down upon meeting a leverage threshold.
• Amortization: Scheduled quarterly payments of $37.5 million beginning for the quarter ending March 31, 2030; remaining balance due at maturity. Amortization may be deferred to maturity if a specified Total Net Leverage Ratio is achieved.
• Security & Covenants: The loan is secured by liens on substantially all assets of TG Therapeutics and certain subsidiaries (guarantors) and contains customary covenants and default remedies (including acceleration by the Administrative Agent).
• Filing items: Reported under Item 1.01 (material agreement) and Item 2.03 (creation of a direct financial obligation).

Why It Matters
This amendment materially changes TG Therapeutics’ debt profile by replacing prior term loans with a longer-dated $750M facility and optional access to up to $250M more. Investors should note the added secured debt, the five-year maturity to 2031, fixed amortization schedule starting in 2030 (with possible deferral tied to leverage), and interest costs tied to SOFR/base rates plus margins that vary with leverage. These are concrete factors that affect the company’s cash obligations, liquidity flexibility, and balance-sheet leverage going forward. The full amendment text will be included as an exhibit to TG Therapeutics’ Form 10-Q for the period ending March 31, 2026.